7月9日,默沙东宣布与Verona Pharma(下称“Verona”)达成协议,将通过子公司以每股107美元的价格收购Verona的美国存托股票(ADS),较其在纳斯达克前一交易日收盘价溢价23%,较60日成交量加权平均价溢价39%,交易预计今年第四季度完成,总价值约达100亿美元。金额之高,一举成为今年生物医药领域第二大并购案,仅次于此前强生146亿美元收购Intra-Cellular。通过...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.